-+ 0.00%
-+ 0.00%
-+ 0.00%

Latigo Biotherapeutics Names Todd N. Smith President and CEO, Succeeding Nima Farzan

PUBT·11/05/2026 11:45:30
Listen to the news
Latigo Biotherapeutics Names Todd N. Smith President and CEO, Succeeding Nima Farzan
  • Latigo Biotherapeutics appointed Todd N. Smith president and CEO, effective immediately, succeeding Nima Farzan.
  • Smith has more than three decades of experience, including leading biopharmaceutical companies through late-stage development and pain therapy launches.
  • Farzan will remain as a strategic advisor through 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Latigo Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050645PRIMZONEFULLFEED9870754) on November 05, 2026, and is solely responsible for the information contained therein.